• Hypothalamic SLC7A14 and Aging-Reduced Lipolysis

  2026-10-05

  Jiang et al. identify hypothalamic SLC7A14 in POMC neurons as a central regulator of the age-associated decline in white adipose tissue lipolysis in male mice. Their findings connect neuronal SLC7A14 to taurochenodeoxycholic acid, intestinal bile acid transport, sympathetic afferent signaling, and mTORC1 activity, expanding the mechanistic framework for brain–gut–adipose communication.

• TCF25, Lysosomal Acidification, and Cell Death

  2026-10-05

  Ren et al. identify TCF25 as a nutrient-stress regulator that links lysosomal acidification to metabolic adaptation and, during prolonged glucose deprivation, lysosome-dependent cell death. The study connects V-ATPase activity, autophagy, ferritinophagy, lysosomal membrane permeability, and hepatic ischemia-reperfusion injury while defining important boundaries for interpreting iron-related interventions.

• dcst2 Loss Does Not Cause Zebrafish Muscle Hypertrophy

  2026-10-03

  A 2025 study used CRISPR/Cas9 mutagenesis in zebrafish to test whether loss of dcst2 explains a human familial association with unusual strength and muscle hypertrophy. The mutant fish developed normally and showed no detectable differences in swimming performance or muscle-fiber size, while male infertility provided evidence for a reproductive role of dcst2.

• Bacitracin B1670: Practical Antibacterial Workflow

  2026-10-01

  Bacitracin (B1670) is a peptide antibiotic for controlled antibacterial research focused on bacterial cell wall and peptidoglycan synthesis disruption. It is suitable for laboratory assay development and comparative bacterial growth studies, but it is not intended for diagnostic, therapeutic, or other medical use.

• Ibrexafungerp: Reliable Candida Assay Workflows

  2026-10-01

  This scenario-driven guide explains how Ibrexafungerp, SKU C8697, can support reproducible Candida susceptibility and viability workflows across neutral and acidic assay conditions. It combines CLSI-based protocol parameters, pH-specific evidence, resistance interpretation, preclinical context, and practical product-selection guidance.

• SPRTN Ubiquitin Binding Drives DPC Proteolysis

  2026-09-30

  A November 2024 bioRxiv preprint identifies a ubiquitin-binding interface within the N-terminal catalytic region of SPRTN, explaining how this protease preferentially targets polyubiquitinated DNA–protein crosslinks. The work links DPC ubiquitination to rapid substrate activation and provides a mechanistic framework for studying genome-protection pathways, while its preprint status requires cautious interpretation.

• SpCas9 mRNA for Causal Genome Engineering

  2026-09-30

  SpCas9 mRNA enables transient, guide-directed genome editing with a translation-optimized RNA architecture. This article explains how its cap, modified nucleotides, localization signals, and assay controls influence causal functional-genomics experiments.

• Zoledronic Acid: Cancer Assay Workflows

  2026-09-29

  Build reproducible Zoledronic Acid experiments for cancer cell apoptosis, breast cancer models, multiple myeloma, and osteolytic bone disease research. This workflow emphasizes solubility-aware handling, dose–time matrices, orthogonal readouts, and mechanism-first interpretation.

• SW033291: Reliable 15-PGDH Workflows

  2026-09-29

  A scenario-driven guide to using SW033291 (SKU A8709) in 15-PGDH, PGE2, hematopoietic, and tissue-repair studies. It connects biochemical potency, formulation controls, concentration-response design, and recent muscle-regeneration evidence to practical laboratory decisions.

• Ibrexafungerp: pH-Aware Antifungal Assay Design

  2026-09-28

  Ibrexafungerp, also known as MK 3118, offers a powerful model for pH-aware antifungal research. This article connects its glucan synthase mechanism with rigorous susceptibility testing, product handling, and responsible translation into Candida infection models.

• 3-Deazaadenosine Hydrochloride in Fibrosis Research

  2026-09-28

  A strategic guide to using 3-Deazaadenosine hydrochloride as an upstream perturbation of SAHH-dependent methyl metabolism in hepatic stellate cell studies—while distinguishing broad methylation effects from the IGF2BP1–m6A–TUBB4B mechanism reported in liver fibrosis research.

• Hydrocortisone Butyrate Research Workflows

  2026-09-27

  Hydrocortisone butyrate supports both glucocorticoid-response assays and controlled-delivery experiments, making it useful for connecting inflammation biology with formulation performance. A PLGA microsphere study highlights why particle properties and ester stability should be measured alongside biological activity.

• Nimbolide Traps PARP1 in BRCA-Mutant Cancer

  2026-09-26

  Li et al. identify RNF114 as a PARylation-dependent ubiquitin ligase that helps remove PARP1 from DNA lesions, and show that nimbolide disrupts this process to increase PARP1 trapping. The study links this mechanism to synthetic lethality in BRCA-mutated cancer and reports activity against PARP inhibitor resistance, while leaving important questions about selectivity and clinical translation unresolved.

• Bay 11-7085: Interpreting NF-κB Causality

  2026-09-25

  Bay 11-7085 is an NF-κB activation inhibitor that can help researchers test how inflammatory signaling relates to cell injury. This article connects ER-stress findings in subarachnoid hemorrhage research to practical experimental interpretation—without treating pathway inhibition as proof of a single mechanism.

• Topotecan in First-Line SCLC: Evidence and Limits

  2026-09-25

  David J. Stewart’s review evaluates topotecan-based combinations as potential first-line options for small cell lung cancer (SCLC), synthesizing promising phase II response rates alongside the key concern of neutropenia. It frames these regimens as investigational rather than established replacements for cisplatin–etoposide, and highlights the need for further comparative trials.

8347 records 1/557 page Next 12345 下5页 Last page